Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncofetal RNA-Binding Protein Targeting.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IGF2BP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IGF2BP1 Recombinant Protein (Full-Length & KH Domain Truncations) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View IGF2BP1 Products |
| Gene Delivery | IGF2BP1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression validation. |
View IGF2BP1 Products |
| Benchmark Ab | Anti-IGF2BP1 Recombinant Antibody Sequence-verified positive control for Western Blot, IP, and IHC. |
View IGF2BP1 Products |
| Validator | IGF2BP1 siRNA Set For target knockdown verification and specificity profiling. |
View IGF2BP1 Products |
| Related Target A | IGF2BP2 Homologous RNA-binding protein; critical for off-target selectivity screening. |
View IGF2BP2 Products |
| Related Target B | IGF2BP3 Oncofetal homolog; co-expressed in multiple aggressive malignancies. |
View IGF2BP3 Products |
| Downstream Target | MYC Key downstream oncogenic mRNA client stabilized by IGF2BP1. |
View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| RNA-Protein Interaction (RPI) Disruption Screening | Truncated KH domain proteins (KH1-4) designed specifically for FP and HTRF assays; sequence verified. |
| Subfamily Off-Target Screening (IGF2BP1 vs. IGF2BP2/3) | Full panel of recombinant human IGF2BP family proteins with >95% purity by SDS-PAGE. |
| Lack of Validated Positive Controls | Recombinant benchmark antibodies and validated siRNA sets included in the assay ecosystem. |
| Cellular Target Engagement Validation | High-titer Lentiviral particles for stable cell line generation to support RIP-qPCR and CETSA. |
Live IGF2BP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IGF2BP1 therapeutics is intensifying, with major players shifting focus from traditional targets to undruggable RNA-binding proteins (RBPs). As an oncofetal protein virtually absent in healthy adult tissues but highly overexpressed in various cancers, IGF2BP1 represents a highly tumor-specific therapeutic node. As first-generation small-molecule inhibitors (disrupting the RNA-binding KH domains) reach preclinical optimization, the next wave of R&D is targeting PROTAC-mediated degradation and RNAi-based therapeutics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (RPI Inhibitor) | Academic/Biotech Consortia | Colorectal Cancer, HCC, Melanoma | In vitro binding assays (Need truncated active KH domain proteins) |
| PROTAC / Degrader | Targeted Protein Degradation Pioneers | Ovarian Cancer, Hematological Malignancies | Ubiquitination & degradation assays (Need high-purity full-length protein) |
| RNAi / ASO | Oligonucleotide Therapeutics Developers | Solid Tumors, Treatment-resistant cancers | Knockdown verification (Need validated siRNA and Lentivirus) |